Guggenheim raised the firm’s price target on Novo Nordisk to DKK 1,013 from DKK 992 and keeps a Buy rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk Initiates Multi-Billion Share Buyback
- Healthcare Stocks Rise despite Medicare Price Cuts for Their Drugs
- Is Berkshire Hathaway (NYSE:BRK.B) Missing Out on AI Tailwinds?
- U.S. to announce prices for drugs in Medicare negotiations, NY Times says
- LLY, NVO: Which GLP-1 Stock Is the Better Bet?